{"eventGroups":[{"description":"Oblimersen 3 mg/kg/day continuous intravenous infusion daily for 7 days on alternated weeks on week 1, 3 and 5 (days 1 through 7, 15 through 21, and 29 through 35); Rituximab 375 mg/m2 intravenous infusion for six doses on days 3, 8,15, 22, 29, and 36.","id":"EG000","otherNumAffected":46,"otherNumAtRisk":46,"seriousNumAffected":15,"seriousNumAtRisk":46,"title":"Oblimersen + Rituximab"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 and 2","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":46,"numEvents":23}],"term":"Anaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grades 1 and 2","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":46,"numEvents":8}],"term":"Thrompbocytopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grades 1 and 2","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":46,"numEvents":3}],"term":"Neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grades 1 and 2","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":46,"numEvents":17}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grades 1 and 2","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":46,"numEvents":9}],"term":"Odema"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grades 1 and 2","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":46,"numEvents":9}],"term":"Rash"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grades 1 and 2","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":46,"numEvents":5}],"term":"Fever"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":46,"numEvents":1}],"term":"Anaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":46,"numEvents":2}],"term":"Thrombocytopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":46,"numEvents":7}],"term":"Neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":46,"numEvents":3}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":46,"numEvents":1}],"term":"Oedema"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":46,"numEvents":1}],"term":"Fever"}],"timeFrame":"2 Years, 10 Months"}